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Could Science-Based Regulation Make Tobacco Products
Less Addictive?
Jack E. Henningfield, Ph.D.* and Mitch Zeller, J.D. +
The marketplace for all tobacco products centers on creating and
sustaining an addiction to nicotine. This addiction ensures a lifetime of
tobacco use by millions of customers. It was with this notion in mind that a
top executive for Brown & Williamson Tobacco Corporation wrote, in
1963, that cigarette companies were not in the business of selling tobacco
products but, rather, were "in the business of selling nicotine, an addictive
drug.''
Thirty-three years later, in the 1996 United States presidential
campaign, candidate Bob Dole stated, "Some people who have tried
[tobacco] can quit easily. Others don't quit. So I guess it's addictive to
some and not to others., 2 Mr. Dole's conclusions that some people can
quit and that not all become addicted are true at face value. His statements
may not have seemed so remarkable had he not been supporting tobacco
company interests, arguing against the general conclusion that tobacco is
addictive. The idea that not all users of addictive drugs become addicted
was acknowledged by the U.S. Surgeon General in 1988. s In fact, it is true
* Jack E. Henningfield is Vice President of Research and Health Policy for Pinney
Associates, Inc. and an Adjunct Professor in the Department of Psychiatry and Behavioral
Sciences at theJohns Hopkins University School of Medicine.
t Mitch Zeller is Vice President for Policy and Strategic Communications for Pinney
Associates, Inc. and is former Associate Commissioner and Director of the Office of
Tobacco Programs of the U.S. Food and Drug Administration.
t Preparation of this Commentary was supported by a Robert Wood Johnson Foundation
Innovators Combating Substance Abuse Award. The authors appreciate the editorial
assistance of Christine A. Rose. The authors provide consulting services regarding
treatments for tobacco dependence to GlaxoSmithKline Consumer Health Care through
Pinney Associates, Inc. Jack Henningfield also has a financial interest in a nicotine
replacement product under development and serves as an expert witness in litigation
against the tobacco industry by the U.S. Department ofJustice and other plaintiffs.
'John Slade et al., Nicotine and Addiction: The Brown and Williamson Documents, 274 JAMA 225,
228 (1995).2Jacob Sullum, Give Dole a Break, N.Y. TIMES, July 12, 1996, at A27.
'SURGEON GENERAL, U.S. DEP'T OF HEALTH & HUM. SERVS., THE HEALTH CONSEQUENCES OF
SMOKING: NICOTINE ADDICTION at v, 253 (1988).
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of all addictive drugs.'
Nonetheless, some characteristics are unique to cigarettes. First, there
is a higher risk of addiction to nicotine in cigarettes than to any other
addictive drug. Second, there is a higher risk of premature death
associated with cigarette smoking than with other addictive drugs.
The Food and Drug Administration (FDA) concluded that seventy-
seven to ninety-two percent of adult cigarette smokers meet the criteria for
dependence. In contrast, pure nicotine products used to treat tobacco
dependence vary in addictiveness, with very low levels associated with
nicotine patches and gum and somewhat higher levels with nasal nicotine
spray. Overall, however, the risk of addiction to these pharmaceuticals is
very low compared to that of cigarettes.5
What is it about cigarettes that make them so addictive? Are they
designed with the intent to create and sustain addiction? Could product
regulation contribute to tobacco disease reduction by reducing the
addictiveness of the products? One argument in favor of pursuing such an
approach is the inescapable reality that the toxicity of tobacco products
makes it extremely unlikely they can be rendered safe. Since cigarette
smoke contains a toxic cocktail of more than four thousand chemicals, the
most we can hope for is a reduction in the level of toxicity by setting
standards for allowable contents and design features. 6
While efforts to make tobacco products less deadly are worthwhile and
should be pursued, we propose that it may be feasible to reduce the
addictiveness of cigarettes and thereby lessen the risk that experimenters
would become addicted. This may also make it easier for addicted persons
to quit. The following Commentary will examine the scientific foundation
and implications for such a regulatory approach. Although our focus will
be on cigarettes, similar principles appear applicable to smokeless tobacco
and other tobacco products.
' See Gary A. Giovino et al., Epidemiology of Tobacco Use and Dependence, 17 EPIDEMIOLOGIC REV.
48, 60 (1995).
*'SURGEON GENERAL, supra note 3, at 213-14.
' See WORLD HEALTH ORG., ADVANCING KNOWLEDGE ON REGULATING TOBACCO PRODUCTS,
Recommendations 2 & 3 (2001), available at http://www5.who.int/tobacco/index.cfm;
Matthew L. Myers, Could Product Regulation Result in Less Hazardous Tobacco Products ?, 3 YALE
J. HEALTH POL'Y L. & ETHICS 139 (2002).
' But see Neal L. Benowitz & Jack E. Henningfield, Establishing a Nicotine Threshold for
Addiction-The Implications for Tobacco Regulation, 331 NEW ENG. J. MED. 123 (1994) (offering
an earlier proposal to render cigarettes pharmacologically non-addictive by removing their
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ESSENTIAL TERMS AND CONCEPTS
The risk of tobacco-caused disease is directly related to the amount
(e.g., cigarettes per day) and duration (e.g., years) of tobacco use.
Addiction is the biological force that drives most tobacco users to patterns
of persistent daily exposure to high levels of deadly tobacco toxins. The
cornerstone of the FDA's evaluation of whether or not nicotine in tobacco
met criteria for classification as a drug hinged on the finding that use of
cigarettes and smokeless tobacco was largely driven by addiction to
nicotine. Nicotine is a powerful and potent drug (about five to ten times
more potent than cocaine in the alteration of mood and behavior) that
naturally occurs in the tobacco plant.8 It has been used as a
pharmacological tool to explore the workings of the nervous system. It has
also been used as a pesticide at high dosages. In small doses, nicotine and
nicotine analogues have potential medical uses such as the treatment of
Alzheimer's disease and ulcerative colitis. 9
Addiction is the general term that is used synonymously with the more
technical term dependence to label regular, compulsive, and maladaptive
self-administration of a psychoactive drug such as morphine, cocaine,
alcohol, or nicotine.0 If an addicted person uses a drug regularly and
persistently, his or her body may develop physiological dependence, such that
a withdrawal syndrome may emerge within several hours to one day after
drug administration is terminated." Dependence and withdrawal can be
diagnosed according to objective criteria outlined by both the American
Psychiatric Association and the World Health Organization." The strongest
reactions, desired and undesired, that are often experienced upon initial
drug exposure tend to diminish over time as a person develops tolerance for
the drug. Tolerance is typically accompanied by an increase in dosage until
a stable level develops. Higher levels of tolerance and drug intake are
associated with higher levels of addiction, and in turn, a higher risk of
8 SeeJack E. Henningfield & Rosemary Nemeth-Coslett, Nicotine Dependence: Interface Between
Tobacco and Tobacco-Related Disease, 93 CHEST 37S (1988).
9 See David J.K. Balfour & Karl 0. Fagerstrom, Pharmacology of Nicotine and Its Therapeutic Use in
Smoking Cessation and Neurodegenerative Disorders, 72 PHARMACOLOGY & THERAPEUTICS 51 (1996);
Paul A. Newhouse et al., Nicotinic System Involvement in Alzheimer's and Parkinson's Diseases-
Implications for Therapeutics, 11 DRUGS & AGING 206 (1997).
10 Bridgette E. Garrett et al., Tobacco Addiction and Pharmacologic Interventions, 2 EXPERT
OPINION ON PHARMACOTHERAPY 1545, 1546 (2002).
1 For example, smoking a pack-per-day for a month or more is assumed sufficient to lead to
abstinence-associated withdrawal in many people.
12 See AM. PSYCHOL. ASS'N, DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS 181,
244-45 (4th ed. 1994); WORLD HEALTH ORG., THE ICD-10 CLASSIFICATION OF MENTAL AND
BEHAVIORAL DISORDERS: CLINICAL DESCRIPTION AND DIAGNOSTIC GUIDELINES, 75-78 (1992).
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adverse health consequences.
The effects of psychoactive drugs are strongly determined by the
amount or dose that reaches the brain, as well as its speed of absorption into
the bloodstream. The amount of a drug that is absorbed into the
bloodstream from a given formulation is referred to as its bioavailability. For
example, only about ten to thirty percent of the 10 milligrams of nicotine
contained in a conventional cigarette is typically absorbed, 13 while about
fifty percent of the nicotine from a 2-milligram piece of nicotine gum is
typically absorbed. 14 The speed of absorption through the lining of the
mouth is enhanced when the molecules of the drug have been liberated of
their electrical charges (i.e., convert to their free base or un-ionized form),
which is accomplished for many psychoactive drugs by use of substances to
increase the alkalinity or pH.
DESIGNED TO ADDICT
The FDA's nicotine investigation hinged on the determination of
whether tobacco product manufacturers intentionally controlled the
nicotine dosing characteristics of their products to facilitate the
development and maintenance of nicotine addiction. The FDA found that
cigarettes and smokeless tobacco products were highly controlled with
respect to their nicotine content, their bioavailable nicotine, and the rate
at which the delivered nicotine could be absorbed into the bloodstream.
The FDA also found that many aspects of cigarette design and
manufacture, including the use of reconstituted tobacco' and various
chemical ingredients, were routinely employed to control nicotine
delivery. Its analysis suggests that cigarette design could be employed
either to increase or decrease the addictive effects of cigarettes by, for
example, increasing what was variously referred to as the nicotine "kick" or
"impact" of cigarettes. In other words, it is evident that addictiveness is not
an all-or-nothing attribute of a product. Rather, a product can apparently
be engineered to become more or less addictive by controlling its physical
properties. With respect to drug products, this concept is well understood,
and drug manufacturers are required to design their products so as to
achieve desired effects while minimizing addictive ones.
Addictiveness is measured in animal and human studies estimating the
level of risk that substance use will lead to addiction according to objective
" Reginald V. Fant et al., Nicotine Replacement Therapy, 26 PRIMARY CARE 633, 634 (1999).
14 Id. at 639.
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criteria. 16 These studies are used by the FDA and the Drug Enforcement
Administration (DEA) to determine whether or not a drug is addictive
and, if so, its level of addictiveness. This information in turn helps the FDA
and the DEA determine product labeling and marketing restrictions.
Because addictiveness can be affected by increases in drug dosage and
the speed of delivery, drug manufacturers design formulations, or drug
delivery systems, to maximize desired effects while minimizing undesired
effects such as addiction. 7 In fact, despite the increasingly widespread
availability of nicotine delivering medications, these products have not
emerged as gateways to nicotine addiction. Although a small fraction of
users continue taking the products for a year or more (apparently out of
the justifiable fear that they will relapse into smoking), the vast majority
use them for less than three months and find them far easier to
discontinue than cigarettes.
These examples are not presented to imply that the addictiveness of
cigarettes can be reduced to the level of nicotine gum, but rather to
illustrate that drug design can increase or decrease psychoactive effects by
controlling the speed of drug delivery and other characteristics. If nicotine
medications and other drug products can be designed to minimize their
addictive effects, and if tobacco products are designed to increase their
addictive effects, could tobacco products be designed with the opposite
intent?
IT'S THE DOSE
In the course of the FDA's investigation of tobacco products, it became
apparent that major elements in product design related to nicotine dose
control, i.e., providing consumers with the most palatable and addictive
forms of nicotine possible. The FDA learned that tobacco companies faced
a great challenge in ensuring adequate nicotine delivery in the years
following the 1964 Surgeon General's report amidst the increasing health
concerns of smokers. Smokers wanted less tar and nicotine. The industry,
however, understood what it was hiding from consumers-nicotine at
dosages high enough to readily sustain addiction is critical to smoking
6 See Donald R. Jasinski et al., Abuse Liability Assessment in Human Subjects, 5 TRENDS IN
PHARMACOLOGICAL SCI. 196 (1984). See also NAT'L INST. ON DRUG ABUSE, U.S. DEP'T OF
HEALTH & HUM. SERVS., NIDA RESEARCH MONOGRAPH 92: TESTING FOR ABUSE LIABILITY OF
DRUGS IN HUMANS (Marion W. Fischman & Nancy K. Mello eds., 1989).
" Although nearly any vehicle for drug delivery might, in principle, be considered a drug
delivery system, whether a substance is regulated as a drug, drug delivery system, or
combination drug and delivery system depends on many factors. WORLD HEALTH ORG.,
ADVANCING KNOWLEDGE ON REGULATING TOBACCO PRODUCTS, supra note 6.
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satisfaction and cigarette preference. Truly low-nicotine cigarettes were
shown as far back as 1945-in a study funded by the American Tobacco
Company-to be unsatisfactory for many smokers.' Subsequent internal
research shows that, to make smoking satisfying, most smokers require
cigarettes that can readily deliver more than approximately 0.8 milligrams
of nicotine per cigarette.19
PRODUCT DESIGN FEATURES THAT SUBVERT THE FEDERAL TRADE
COMMISSION METHOD
To provide a standardized method for determining tar and nicotine
yields, the Federal Trade Commission (FTC) adopted a machine test
developed by the American Tobacco Company in the 1930s.' Although the
FTC recognized that intake from individual smokers could vary, it assumed
that the method would provide consumers with a fair means of
differentiating among cigarette brands on the basis of their expected,
relative deliveries of tar and nicotine. This testing method was also
intended to provide cigarette manufacturers an incentive to design their
cigarettes so that tar and nicotine deliveries would be reduced. Instead, the
industry deliberately designed cigarettes to yield tar and nicotine deliveries
on the machine test that they knew were substantially lower than the levels
delivered in "real world" smoking by actual smokers. l
The FTC testing method essentially involves the use of smoking
machines programmed to take 35-milliliter puffs every minute until the
cigarette has burned to 3 millimeters below the filter paper overwrap,
which holds the filter to the tobacco tube portion of the cigarette (typically
leaving two to four puffs worth of tobacco unsmoked) .2 By contrast,
humans take puffs at a rate nearly double that of the machines-at
intervals of thirty to forty seconds-and can smoke beyond the point that
machines stop.23 Since each puff becomes more concentrated in tar and
'
8J.K. Finnegan et al., The Role of Nicotine in the Cigarette Habit, 102 ScI. 94 (1945).
" Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco To
Protect Children and Adolescents, 61 Fed. Reg. 44,396, 44,887 (Aug. 28, 1996) (to be
codified at 21 C.F.R. pt. 801).20 J.A. Bradford et al., Nature of Cigarette Smoke: Technique of Experimental Smoking, 28 INDUS. &
ENG'G CHEMISTRY 836 (1936).
2 Richard D. Hurt & Channing R. Robertson, Prying Open the Door to the Tobacco Industry's
Secrets About Nicotine: The Minnesota Tobacco Trial, 280JAMA 1173, 1178 (1998).
2 NAT'L CANCER INST., U.S. DEP'T OF HEALTH & HUM. SERVS., SMOKING AND TOBACCO
CONTROL MONOGRAPH 7: THE FTC CIGARETTE TESTING METHOD FOR DETERMINING TAR,
NICOTINE, AND CARBON MONOXIDE YIELDS OF U.S. CIGARETTES 9-14 (1996).
" James C. Zacny & Maxine L. Stitzer, Human Smoking Patterns: The FTC Cigarette Test for
Determining Tar, Nicotine, and Carbon Monoxide Yields of U.S. Cigarettes, in NAT'L CANCER INST.,
111: 1 (2002)
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nicotine, just a few extra puffs can result in a substantially greater intake.
Cigarette manufacturers could have designed their cigarettes so that
tar and nicotine intake by smokers would generally correspond to FTC test
ratings. In fact, such cigarettes have been used by researchers. 4
Alternatively, they could have suggested to the FTC how to conduct tests
that would measure maximal exposures and not substantially under-
represent what humans would receive (this is the standard for food and
drug labeling).
However, cigarette companies were faced with a dilemma. Consumers
increasingly expressed the desire for reduced-tar and nicotine-rated
cigarettes, but the flavor and satisfaction derived from smoking was
strongly related to the amount of tar and nicotine delivered. Diminished
levels of nicotine resulted in unsatisfying cigarettes and withdrawal
symptoms, fostering growing concern in the tobacco industry that
substantial reductions in nicotine delivery could lead to the erosion of the
entire cigarette market. 5 Therefore, cigarette companies used creative
designs to beat the FTC test method, allowing them to advertise their
cigarettes with lower tar and nicotine ratings while still delivering full doses
of both. In practice, this meant there was virtually no relation at all
between cigarette ratings and actual human nicotine blood levels.2 5 One
study showed that tar deliveries from typical smoking are approximately
two to three times greater than FTC-rated levels. 6
One tobacco company document bluntly stated its challenge as
follows: "Irrespective of the ethics involved, we should develop alternative
designs (that do not invite obvious criticism) which will allow the smoker
to obtain significantly enhanced deliveries should he so wish." 27 Another
document raised the following questions before approving cigarettes that
tested low on machine tests yet provided no demonstrated safety benefit:
Should we market cigarettes intended to reassure the smoker that they
are safer without assuring ourselves that they are indeed so or are not less
U.S. DEP'T OF HEALTH & HUM. SERVS., SMOKING AND TOBACCO CONTROL MONOGRAPH 7: THE
FTC CIGARETTE TESTING METHOD FOR DETERMINING TAR, NICOTINE, AND CARBON MONOXIDE
YIELDS OF U.S. CIGARETTES 154-56 (1996).
24 See Roland R. Griffiths et al., Human Cigarette Smoking: Manipulation of Number of Puffs Per
Bout, Interbout Interval and Nicotine Dose, 220 J. PHARMACOLOGY & EXPERIMENTAL
THERAPEUTICS 256 (1982); Jack E. Henningfield et al., Abuse Liability and Pharmacodynamic
Characteristics of Intravenous and Inhaled Nicotine, 234 J. PHARMACOLOGY & EXPERIMENTAL
THERAPEUTICS 1 (1985).
25 Hurt & Robertson, supra note 21, at 1176.
21 See Mirjana V. Djordjevic et al., Doses of Nicotine and Lung Carcinogens Delivered to Cigarette
Smokers, 92J. NAT'L CANCER INST. 106 (2000).
27 Hurt & Robertson, supra note 21, at 1176.
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safe? For example, should we "cheat" smokers by "cheating" League
Tables (the British equivalent of the FTC test)? Should we use our
superior knowledge of our products to design them so that they give low
League Table positions but higher deliveries on human smoking?28
In essence, the FTC test came to the rescue of the tobacco industry and
proved to be among its most powerful marketing tools because it gave
manufacturers a course to follow and a credible "government-endorsed"
communication."' It enabled the industry to achieve its dual goal of
marketing cigarettes for their reduced nicotine (and tar) while actually
sustaining addictive nicotine dosage levels. Manufacturers cited the FTC
test to support their claims of reduced tar and nicotine even as they
designed cigarettes to nimbly dodge the test and give smokers all the tar
and nicotine they desired-for a satisfying smoking experience that
maintained their addiction.
The following design features allow cigarettes to provide several times
higher levels of exposure to tar and nicotine than their FTC ratings:
* Whether advertised as "ultra-low" or "full-strength," all cigarettes
contain several times more nicotine than consumers "need" per
cigarette.
* Cigarettes can "hide" more nicotine under the filter overwrap, thus
making more tobacco available to a smoker than to the FTC machine.
* Ventilation holes in the filter allow up to ninety percent ambient air to
be collected with each puff on the machine, but the holes are
frequently covered by the fingers and / or lips of human smokers
because they are typically hidden and there is no direction not to cover
them.
* Increased use of burn accelerants make cigarettes burn faster between
puffs and, therefore, send more "sidestream" smoke into the ambient
air that is not collected by the machine. Human smokers inhale some
of this sidestream smoke and also puff more frequently, so a larger
fraction of the tobacco is inhaled.
In the course of beating the FTC method, tobacco companies
simultaneously developed techniques to provide more "kick" per milligram
of delivered nicotine. Several design features undoubtedly contributed to
28 Id. at 1178.
See Judith Wilkenfeld et al., It's Time for a Change: Cigarette Smokers Deserve Meaningful
Information About Their Cigarettes, 92J. NAT'L CANCER INST. 90 (2000).
" "Kick" is a tobacco industry term often used to describe the pharmacological effect of
111:l1 (2002)
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both the subversion of the FTC method and the enhancement of addictive
effects. This enabled the industry to produce cigarettes that were even
more addictive, and, at the same time, claim lower nicotine yields in its
advertising.
The following techniques could have plausibly increased the kick per
milligram of delivered nicotine:
* Chemically control the pH of the tobacco to increase the transfer of
nicotine from tobacco to smoke aerosol in a free base gas form that is
not detected by the FTC machine but that may have a strong impact on
upper airway receptors and be more readily absorbed.
* Engineer the cigarette so that the smoke will be at an optimal pH to
increase the fraction of nicotine in the smoke that is quickly absorbed.
* Employ aerosol-engineering techniques to increase the fraction of
smoke particles that can be inhaled deep into the lung and thus enable
more complete absorption of nicotine (and probably carcinogenic
lung toxins as a side effect).
" Increase acetaldehyde in the smoke as shown by Philip Morris
researchers to enhance the addictive effects of nicotine.
" Add menthol and / or other ingredients to enable larger and more
deeply inhaled puffs, thereby increasing nicotine doses.
Based on our understanding of pharmacology and drug design, and on
information in tobacco industry documents, the following design features
and ingredients may have made smoking more pleasant, even though they
may have also made cigarettes more toxic:
" Cigarette ventilation dilutes the smoke, requiring larger volumes to
obtain the same nicotine doses. (This is analogous to diluting vodka
with water, thereby producing a milder beverage but one that is no less
intoxicating than the undiluted version.)
" Leuvenalic acid appears to have been used to smooth the smoke a user
inhales.
* Menthol provides a throat-soothing effect, which could make highly
toxic smoke feel smoother and lighter.
" Glycerin can carry nicotine particles deep into the lung as well as
provide a "smoother" smoke.
nicotine that is important in keeping smokers hooked.
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It is important to note that there has been little systematic evaluation of
these pleasure-enhancing modifications by experts outside the tobacco
industry. These features are presented as examples of cigarette
characteristics that may have the intended effects that we postulate. In
principle, the FDA could require the tobacco industry to disclose the
effects of such alterations and to justify their application.
USING REGULATORYAUTHORITY TO ALTER PRODUCT CHARACTERISTICS AND
REDUCE ADDICTIVENESS
So far, we have examined controllable ingredients and design features
that plausibly enhance the addictiveness of cigarettes, increase their
toxicity, and / or contribute to misleading estimates of human exposure to
nicotine and tar. To protect the public, Congress could grant the FDA
authority to prohibit their use or set performance standards. For example,
if particle size can be controlled to decrease the fraction of particles that
can be absorbed in the lungs, the FDA might set an allowable absorption
percentage. Similarly, if ammonia increases the addictive kick of nicotine
doses, and if menthol enhances the rapid absorption of nicotine deep into
the lungs and increases carcinogenicity, such compounds might be
prohibited. Finally, if pH manipulations increase the speed of nicotine
absorption, standards might be set to diminish the rate of absorption.
In general, performance standards can be based on allowable
ingredient levels, design and manufacturing techniques, or empirical tests
of actual performance. There are precedents from food and drug
regulation that can be adapted to many aspects of tobacco product
regulation.3 This does not imply the need to tell manufacturers how to
make their products; it merely ensures that public health considerations
drive the FDA's scrutiny of product design and manufacture. Such
oversight stands in stark contrast to the current unregulated environment
in which tobacco companies are free to use any methods at their disposal,
including techniques that maximize rather than minimize addictiveness. In
principle, a wide range of standards could be set that would not render
cigarettes unacceptable, incapable of delivering nicotine, or even non-
addictive. However, if such strategies could contribute to incrementally
reduced cigarette addictiveness, then they warrant exploration. The idea is
.similar to striving for incremental reductions in cigarette toxicity through
performance standards such as allowable maximums for nitrosamines,
pesticide residues, arsenic, carbon monoxide, and other substances. Such
s' 21 C.F.R. §§ 1, 801 et seq. (2002); Jack E. Henningfield et al., A Proposal To Develop
Meaningful Labeling for Cigarettes, 272 JAmA 312 (1994).
111: 1 (2002)
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performance standards are unlikely to lead to safe and non-addictive
cigarettes in the near future, but if they reduce disease prevalence and
morbidity, their exploration is justifiable.
We are well aware of the potential unintended consequences of what
we propose. For instance, non-smokers may initiate tobacco use under the
mistaken impression that cigarettes have been made non-addictive, rather
than merely less addictive. There is also the possibility that being a little bit
addictive is no different than being a little bit pregnant. Such broad,
population-based concerns should be at the forefront of the FDA's
examination of whether regulatory powers should be used to make tobacco
products less addictive.
IMPLICATIONS FOR OTHER TOBACCO PRODUCTS
Available data and documents indicate that it is also possible to reduce
the addictiveness of smokeless tobacco products by setting ceiling levels on
the use of buffering compounds. In addition, it is possible to determine
product characteristics that are particularly appealing to and effective in
establishing smokeless tobacco use among children. Such appealing
designs and ingredients could be restricted.
Cigars and pipes pose a separate dilemma. It is important not to leave
any category out of a regulatory framework lest we send the implicit
message that there is less concern about that product category. However,
the challenge is greater with cigars and pipes because there are far fewer
data on these products.
IMPLICATIONS FOR LABELING AND ADVERTISING
The major tobacco companies do not label or advertise their tobacco
products as addictive." This is a major flaw in the existing consumer
warning system. There has been extensive theoretical discussion on how
much nicotine would render a cigarette addictive. Until such values are
empirically established, all tobacco products should include a strong
33
addiction warning.
32 The fact that there is no regulatory barrier to such warnings has been demonstrated by
several small companies, which provide some form of addiction warning on their tobacco
products. See, e.g., Star Scientific, Inc., StonewallTM brand snuff, at
http://www.starscientific.com; Vector Tobacco, OmniTM cigarettes, at
http://www.omnicigs.com.
" All nicotine-containing tobacco products should include a strong warning that they are
addictive. Such warnings provide vitally important consumer information but should in no
way relieve manufacturers of responsibility, or any accompanying legal liability, for creating
and sustaining addiction among consumers.
11
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As for how to appropriately label a cigarette with sub-biologically active
levels of nicotine, we leave the question for another day. The challenges
involved are extraordinarily complex; they comprise a whole other
category of issues that require comprehensive regulatory oversight. For
now, however, it bears mentioning that non-alcoholic beer typically
contains small amounts of alcohol. 34 Similarly, "fat-free" foods may contain
trace levels of fats but their labels may say that there is "not a significant
source of calories from fat. 35 Perhaps a label such as "may promote
nicotine addiction" should be considered for "nicotine-free" or "de-
nicotinized" cigarettes, given the uncertainty of 1) what nicotine content
might qualify as "nicotine-free" or "de-nicotinized," and 2) whether
exempting "nicotine-free" or "de-nicotinized" cigarettes from bearing an
addiction warning will actually lead to nicotine addiction through a
31graduation process.
CONCLUSION
Considering the extent to which determinants of addiction risk for
cigarettes and other forms of tobacco are controllable, it is plausible that a
regulatory approach can reduce the addiction risk of tobacco products.
Regulation could reduce tobacco use and tobacco-caused disease without
banning tobacco products and without rendering them nicotine-free. This
approach is worth exploring, especially if it is simply not possible to make
tobacco products substantially less toxic.
"' Beer can be labeled as "non-alcoholic" if it contains less than 0.5% alcohol by volume,
provided that the label includes the statement "contains less than 0.5 percent alcohol by
volume." 27 C.F.R. § 7.71e (2002).
"5 "Fat-free" food contains less than 0.5 grams of fat per serving (considered a "trivial level"
of fat). A 0-gram standard is analytically impossible to measure. See Food Labeling; General
Requirements for Health Claims for Food, 58 Fed. Reg. 2478-2536 (Jan. 6, 1993) (to be
codified at 21 C.F.R. pt. 101).
" Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco To
Protect Children and Adolescents, 61 Fed. Reg. 44,396, 44,887 (Aug. 28, 1996) (to be
codified at 21 C.F.R. pt. 801).
111:1 (2002)
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